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was less than 4 years, with any type of myelodysplasia and monosomy 7. All other patients, including older children BOUT 40 YEARS ago two forms of chronic myelocytic leukemia (CML) were recognized in children. One had the typical features of CML of adulthood and usually with monosomy 7, were classified according to FAB criteria. The revised classification led the authors to propose a new appeared in children older than 4 years; the other affected younger children and presented as a myelomonocytic prolifprognostic scoring system. 20 Although the aim of providing an improved system of risk assessment is laudable, the utility eration associated with hemorrhage, infection, lymphadenopathy, and skin rash. The prognosis of the latter group of of the scoring system proposed by Passmore et al 20 may be compromised by the criteria they used to reclassify cases of patients was invariably poor. [1] [2] [3] In subsequent attempts to identify clinico-biological features that would further dischildhood myelodysplastic syndrome (MDS). In particular, some categories, such as the monosomy 7 syndrome, are criminate between these leukemias, Reisman and Trujillo 4 found the absence of the Philadelphia (Ph) chromosome to widely debated or not accepted by some investigators. 18, 19 Thus, the uncertainty of diagnostic criteria in this group of be a hallmark of the juvenile-type entity (JCML). Signs of disturbed erythropoiesis were also reported to be typical of disorders can be expected to limit the utility of the proposed scoring system. JCML, including low levels of hemoglobin (Hb) A 2 and erythrocyte carbonic anhydrase, 5 together with a marked inIn an effort to resolve most of the above described discrepancies, the International Juvenile Myelomonocytic Leukemia crease of HbF, 6 and glucose-6-phosphate dehydrogenase activity. 7 Maurer and others concluded that JCML is accompaWorking Group has recently proposed the term juvenile myelomonocytic leukemia (JMML; R. Castleberry, personal nied by a reversion to fetal-like erythropoiesis. [8] [9] [10] The observation of chromosomal translocations in leukemic bone communication, December 1996), which has been accepted and widely used in some recent publications. [21] [22] [23] It will be marrow cells of different lineages suggested that the pathologic process might involve a multipotent stem cell.
7, 11 We used throughout the remainder of this review. review here the salient clinical and biological features of EPIDEMIOLOGY this disease, emphasizing recent advances in its treatment and in understanding its pathological origin.
The exact incidence of JMML is not yet known. In the only population-based study reported to date, 18 ,24 JMML ac-
CLASSIFICATION
The classification of chronic childhood myeloproliferative Polyclonal hypergammaglobulinemia is also common, but An analysis of peripheral blood usually provides more
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Other abnormalities 32 16 reliable diagnostic information than does an examination of Data from 11, 13, 15, 20, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . Certain features are not reported for all pathe bone marrow smear. Typically, marrow cellularity is tients.
increased, with the vast majority of cells belonging to the myeloid series in all stages of maturation. Monocytes accounted for 18% of all cases of myelodysplastic syndrome in count for 5% to 10% of all myeloid cells, with the blast cell children less than 15 years old and 1.62% of all hematologic population far below the level seen in acute leukemia. Folmalignancies (0.61 new cases per year per million children low-up marrow evaluations rarely yield informative results. at risk). The disease predominates in children younger than
In contrast to other types of childhood leukemia, JMML has 4 years with 40% of cases occurring before the age of 1 year few discernible constitutional or clonal chromosome abnorand 60% before the age of 2; however, 26% of patients with malities, partly explaining the slow progress in understand-JMML are 3 years of age or older. Boys are affected more ing the pathobiology of this disease. In one study, 68% of often than girls (M/F ratio, 2.5). Associated conditions inthe reported cases of JMML lacked cytogenetic abnormaliclude neurofibromatosis type 1 (NF1) [25] [26] [27] in 7%, and a varities, the remainder having either dissimilar lesions (16%) or ety of occasional clinical abnormalities in an additional 9% monosomy 7 (16%). [46] [47] [48] of cases. At least three pairs of affected twins have been More recently in a retrospective analysis of 110 patients described. 15, 20, 28 In another study, an identical twin was defined by entry criteria and treated in five European counhealthy at the time his brother presented with JMML and tries, 19 the European Working Group on Myelodysplastic remained free of leukemia during preparation of the written Syndromes in childhood (EWOG-MDS) found a constellareport. 29 tion of features to have diagnostic relevance: hepatosplenomegaly in greater than 90%, lymphadenopathy in 76%, pal-CLINICAL AND LABORATORY FEATURES lor in 64%, fever in 54%, skin rash in 36%, absence of the 9;22 translocation, bone marrow blasts less than 20%, and The onset of JMML is often heralded by acute or subacute symptoms of a recent infection. Additional criteria required for definite diagnosis included of age had a significantly higher probability of long-term survival than did older patients; there was no significant at least two of the following: spontaneous in vitro growth of granulocyte-macrophage progenitors (CFU-GM), HbF eldifference between infants presenting at the age of less than 6 months or 6 to 12 months. These relationships were valid evated for age, peripheral blood myeloid precursors, leukocyte count greater than 10 1 10 9 /L, and chromosomal abnorwhether patients treated with bone marrow transplantation were excluded (Fig 1) or included (not shown) in the analymalities.
sis. This analysis should be regarded with caution both because we can only refer to published data and because data
NATURAL COURSE OF THE DISEASE AND PROGNOSTIC
were taken from sources without uniform entry criteria and
FACTORS
do not represent randomized clinical trials. The observation of patients who either were not treated Among the proposed unfavorable risk factors are a low or did not respond to treatment has provided useful informaplatelet count and an increased HbF level 15, 20 (Table 2 ). In tion on the natural history of JMML. Approximately one a recent review of their single-center series of childhood third of the patients present with a rapidly progressive dis-MDS patients, Passmore et al 20 advocated a pediatric scoring ease in which cachexia, organomegaly, and complications system based on HbF level, platelet count, and cytogenetic of marrow failure may lead to early death, whether or not results. The so-called FPC score was predictive of a good treatment is instigated. About another third of the patients prognosis (60% survival at 5 years) when HbF was greater show a more indolent disease course characterized by clinithan 10%, platelets greater than 40 1 10 9 /L, and clonal cytocal improvement with partial or even complete normalization genetic abnormalities were absent. of the blood count after minimal or no treatment. Such patients may enjoy a stable clinical remission, even when there PATHOBIOLOGY is persistence of a variable pattern of disease markers, including splenomegaly, moderate leukocytosis, or monocytosis.
Two consistent abnormalities have been shown by in vitro During this true chronic phase of the disease, they may occastudies of JMML patients: the exuberant spontaneous growth sionally experience reactivation of their leukemia, someof colony forming units-granulocyte/macrophage (CFUtimes in association with infectious episodes. Because these GM) in the absence of exogenous growth factors, [51] [52] [53] [54] and episodes are often self-limiting, introduction of chemotherthe impaired growth of normal hemopoietic progenitors. apy at this time may produce what appears to be a clinical Spontaneous cell growth has been ascribed to the peculiar response. The ultimate outcome of leukemia is difficult to hypersensitivity of the JMML bone marrow or peripheral predict, but a significant proportion of patients eventually blood progenitors to very low levels of cytokines and growth develop massive disease reactivation evolving into a rapid factors probably produced by adherent cells. 55 Removal of progression, often referred to as blastic crisis. 15, 29, 49 The remonocytes by adherence to plastic before culture of bone maining patients have an intermediate prognosis.
marrow or peripheral blood progenitor cells abrogates sponBecause the course of JMML is highly variable and the taneous growth. 55 The observed hypersensitivity response therapeutic choices wide, some investigators have attempted appears to be quite selective, as it occurs in tests with GMto identify factors that predict outcome or at least time to CSF, but not other growth factors regulating early steps of progression. The major role in defining prognosis seems to myelopoiesis, such as inteleukin-3 (IL-3) or granulocyte colbe played by age at the time of disease onset. Most published ony-stimulating factor (G-CSF). 52 To date, binding studies series support the generalization that children who develop and molecular analysis of the GM-CSF receptor have shown the disease when younger than 1 or 2 years have a longer no abnormality, 56 although several provocative clues have emerged (Fig 2) . During neoplastic transformation of mysurvival. 15, 20, 30, 50 eloid progenitors, RAS genes often acquire activating point inactivation of NF1 with consequent Ras deregulation plays an important role in leukemogenesis in children with NF1 mutations that lead to elevated levels of Ras-GTP, resulting in constitutive activation of this common signal transduction who develop JMML. This idea is reinforced by a number of observations in mice with a targeted disruption of Nf1. First, pathway. 57 In this regard, mutated RAS genes have been found in 30% of cases of JMML.
34, [58] [59] [60] In one series most heterozygous Nf1 mice are predisposed to myeloid leukemia and these leukemias delete the wild-type Nf1 allele. 64 Secof the patients with mutated RAS were in the older age group with poor prognosis. 34 Loss of the normal NF1 allele is a ond, fetal hematopoietic cells from embryos with homozygous inactivation of Nf1 show a pattern of selective in vitro common finding in JMML cells from patients with NF1. 61, 62 As a tumor suppressor, the NF1 protein acts as GTPase, GM-CSF hypersensitivity that is reminiscent of that seen in JMML. 62, 63 Finally, transplanting these Nf1 0/0 fetal liver which in turn downregulates Ras-GTP. Primary leukemic cells from children with NF1 show a selective decrease in cells into irradiated recipients consistently induces a myeloproliferative disorder with clinical and pathologic features NF1-like GTPase activating protein (GAP) activity for RAS, but retain normal cellular GAP activity. Leukemic cells also of JMML 62 (K.M. Shannon, personal communication, December 1996) . Taken together these human and murine data show an elevated percentage of Ras in the GTP-bound conformation. 63 These genetic and biochemical data from studies point to deregulated signaling through the RAS pathway as the central event in the abnormal growth of JMML progeniof primary JMML cells strongly support the hypothesis that 54 or in suppression of normal graftment of the human JMML stem cells in primary and hematopoiesis. 53 Bagby et al 54 reported that monocytes from secondary SCID mice should provide a model with which these patients secrete high levels of IL-1, which in turn stimto further delineate the stem-cell properties of JMML.
71
ulate the release of another growth factor(s) by normal accesThe relationship between JMML and childhood monosory cells. In recent studies, an IL-1 receptor antagonist was somy 7 syndrome is uncertain. Both disorders share several reported to inhibit spontaneous JMML proliferation in clinical features including a young age at diagnosis, a previtro. 66 Tumor necrosis factor (TNF) a has been suggested ponderance of male patients, prominent hepatosplenomegto inhibit normal hematopoietic progenitors, 53 resulting in aly, myelomonocytic proliferation, increased frequency of anemia and thrombocytopenia, both clinical hallmarks of NF1, and a poor prognosis when treatment consists of che-JMML.
motherapy without marrow rescue. 16, [72] [73] [74] However, JMML The involvement of the erythroid lineage is a common patients without demonstrable monosomy 7 tend to have feature of JMML, as indicated by the presence of mature higher HbF levels, 19 more pronounced lymphadenopathy, but morphologically aberrant erythroid cells, the conversion and more severe skin rashes than do patients with monosomy to a fetal-type erythropoiesis, and the abnormal in vitro 7, who show a tendency to develop leukopenia and bacterial growth properties of peripheral erythroid progenitors. 52, 67 infections. 16, [72] [73] [74] [75] The majority of patients with JMML do not Cytogenetic analysis of burst-forming unit-erythroid (BFUhave monosomy 7 at diagnosis, whereas others acquire the E) colonies from patients with a chromosome marker sugcytogenetic abnormality only at the time of the disease progested that JMML may arise from early progenitors capagression. 28 , 41 In a study that failed to detect the loss of heteroble to differentiate into monocytic-macrophage-erythroid zygosity (LOH) of chromosome 7 in patients with JMML, cells.
38, 39 The involvement of the erythroid lineage in this Butcher et al 76 speculated that JMML and monosomy 7 are clonal disorder has been also confirmed by the observation distinct disorders that share some, but not all, of the multiple of increased expression of GATA-1, erythropoietin receptor, steps commonly seen in malignant transformation. This idea and a and g globin genes in JMML. 68 More recently, loss has gained further support from a recent study in which of the normal NF1 allele in erythroblasts harvested from the molecular analysis failed to show microscopic deletions of BFU-E colonies of JMML patients has added support to this 7q in 22 cases of JMML.
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hypothesis.
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Several lines of evidence indicate the clonal nature of TREATMENT JMML. First, clonality was shown by the presence of a cytogenetic marker in the bone marrow of rare patients with The treatment of JMML continues to generate contro-JMML, 38 and more recently by a clonal pattern of X chromoversy. Early therapeutic attempts by Lilleymann, using sesome inactivation in girls with this disease. 56 Loss of the quential subcutaneous cytarabine and oral mercaptopurine, normal NF1 allele in CD34 / cells in some JMML patients provided some improvement in the condition of patients, but represents a third independent line of evidence. 69 Cell separanot in survival time. 13 Castro-Malaspina et al 15 reported the tion studies have also traced the origin of JMML stem cells failure of various treatment modalities, including chemotherto the level of the most primitive myeloid progenitor. 56, 69 apy with 6-mercaptopurine (with or without prednisone) in Highly purified CD34 / CD38 0 early progenitor cells (as well 27 patients and more intensive chemotherapy in four paas the reticulocytes, platelets, monocytes, and granulocytes) tients. Regardless of the type of regimen, chemotherapy from a JMML patient have been shown to be clonally derived never resulted in a complete remission (CR) in this large when examined by HUMARA (human androgen receptor series. These investigators concluded that neither splenecassay). 56 Loss of the normal NF1 allele in unfractionated tomy nor radiotherapy nor moderate or intensive chemotherbone marrow samples and in CD34
/ cells lends further supapy was of value in the treatment of JMML. Thus, during a port to this view. The chronic and rapidly progressive (blast period when vastly improved results were being reported for crisis) phase of JMML 15 is likely to have the same clonal most childhood leukemias, the prognosis for JMML reorigin. In one report, a child with JMML and cytogenetic mained poor. evidence of monosomy 7 developed pre-B acute lymphoblasExperience over the past decade suggests that a subset of tic leukemia 49 ; the karyotypic analysis of the lymphoblasts patients with JMML will become long-term survivors when in this case confirmed the presence of monosomy 7, as typitreated exclusively with chemotherapy. Chan et al 32 treated cally seen in pure stem cell disorders such as the Ph-chromofour children with an intensive AML-type regimen, three of some-positive CML, in which involvement of both lymphowhom relapsed after 11 to 21 months with one remaining in cytes and myeloid cells is well recognized. 70 Whether JMML CR at 27 months follow-up. The outcome was superior to represents a true stem cell disorder or the consequence of that in five children, who received less intensive therapy, all malignant transformation occurring in hematopoietic cells of whom died within 1 to 29 months. Despite obtaining restricted to the myeloid differentiation remains controverhematological remission, ie, reversal of the blood counts to normal within 4 to 8 weeks of initiating therapy, with intensial. Miles sive chemotherapy, usually directed to AML, Festa et al 33 native agents, including cytokines and biological response modifiers. Castleberry et al 79 recently described the efficacy were unable to eradicate extramedullary disease in their six patients, who all showed persistent hepatosplenomegaly and of isotretinoin in producing durable clinical and laboratory responses in 10 children with this disease, two of whom thus failure to achieve complete remission; all of the patients experienced hematologic relapse and died of disease at a had complete remissions, three partial remissions, and one a minimal response; the remaining four patients had progresmedian of 8 months. In his recent report on the use of intensive chemotherapy for childhood MDS, Hasle et al 78 desive disease. Of the seven patients who did not undergo BMT, one was in complete remission 83 months after diagscribed 20 patients with this syndrome, including 8 with CMML who were treated with AML-type therapy; only 2 nosis, and two others had stable disease at 36 and 37 months while still receiving isotretinoin. Although clearly warentered remission.
In our literature review we identified 171 children treated ranting further study, these data should be evaluated cautiously. First, a clinical response, defined by the authors as for JMML, with or without bone marrow rescue, for whom there was adequate information to correlate the duration of a reduction of leukocytosis, does not include the correction of cytopenia. Moreover, it is well known that some patients survival with the type of therapy. Fourteen of the 50 nonintensively treated patients (28%) were still alive after 1 to with JMML can have long periods of stable disease (up to 10 years), even when untreated. Additionally, the very young 307 months of follow-up (median 9 months), compared with only 3 of 30 (10%) who received intensive chemotherapy age of 10 patients who received isotretinoin (median, 10 months), probably had a favorable influence on outcome (surviving at 32, 36, and 120 months). Comparison of estimated survival probabilities suggests that intensive chemo-( Table 2) . The apparently increased sensitivity of the JMML cells to therapy is not superior to nonintensive chemotherapy or even to no chemotherapy (Fig 3) . These findings should be interinterferon-a, 14 together with successful use of interferon for CML, 80 prompted some investigators to administer this cytopreted with caution because again we can only refer to published data, which were taken from sources without uniform kine to patients with the juvenile form of the disease.
15,29
The results are difficult to evaluate because of the limited entry criteria, did not consider proposed risk factors (Table  2) cytogenetic abnormality should not be considered a diagnostic contraindication of JMML; patients with well-documismatched donors, and 6 of 19 with matched unrelated donors. The estimated survival for patients treated with grafts mented evidence of JMML and age greater than 1 year at disease onset should be considered at higher risk for rapidly from HLA-matched familial donors appears significantly better than results achieved with any other treatment modalprogressive disease and thus possible candidates for early BMT from an HLA-identical sibling or an unrelated donor. ities (Fig 3) . Attempts to decrease the leukemic blast cell infiltrate or to ameliorate the degree of cytopenia, such as Younger patients may benefit from nonintensive treatment, such as 6-mercaptopurine, 6-thioguanine, or isotretinoin. In aggressive cytoreduction or splenectomy, may be helpful in some cases as a means to reduce the risk of peritransplant general, patients should not be subjected to intensive chemotherapy or BMT with poorly matched donors unless their complications, but there is no evidence that such procedures may actually improve the survival rate or even reduce the clinical course during the first few weeks or months is unusually aggressive or strongly suggestive of a blastic crisis. risk of post-transplant leukemic relapse. 83 The largest study of allogeneic BMT in JMML reported to date 83, 84 indicates Experimental agents are justifiable in children with unfavorable risk features who lack an acceptable marrow donor. that a preparative regimen consisting of busulfan and other cytotoxic drugs offers a higher likelihood of event-free-surMeanwhile, it will be important to clarify the origin of fetal erythropoiesis in patients with JMML, the relationship bevival (due to lower rate of leukemic relapse) in children with an HLA-compatible relative donor than does any other tween monosomy 7 96 and presenting clinical features, and the mechanisms that allow the disease to progress to blastic modality including total-body-irradiation. 85 As a result, this regimen is currently being used in the EWOG-BMT cooperacrisis. tive study. now under investigation in model systems. 
